spinforcashrealmoneyslotsgame&riskfree| Baicheng Pharmaceutical: The subsidiary received the BIOS2207 drug clinical trial approval notice

Securities Times e Company Newsspinforcashrealmoneyslotsgame&riskfree, Baicheng Pharmaceutical (301096) announced on the evening of May 12spinforcashrealmoneyslotsgame&riskfreeZhejiang Thermo Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently received a clinical trial approval notice from the State Food and Drug Administration. The company's independently developed drug BIOS2207 will conduct clinical trials. BIOS2207 is indicated for the treatment of adults and children 4 years of age and older with partial seizures, with or without secondary generalized seizures.